M.A. MELNIKOVA¹, V.I. RUZOV², R.KH. GIMAEV², A.M. VOROBEV³, A.M. IBRAHIM²

 ¹City Polyclinic no. 5, Ulyanovsk

²Ulyanovsk State University, Ulyanovsk

³Central City Clinical Hospital, Ulyanovsk

 Contact details:

Melnikova M.A. — PhD (medicine), Head of the Department of Radiation Diagnostics, ultrasound diagnostics doctor

Address: 11 Prospekt Sozidateley, Ulyanovsk, Russian Federation, 432067, tel.: +7-927-810-69-97, e-mail: maschulka1@rambler.ru

The purpose — to determine the level of angiotensin II early after myocardial infarction and its relationship with cardiac structural parameters, as well as the role of this biomarker in the occurrence of recurrent cardiovascular events.

Material and methods. The study included 96 patients with new onset myocardial infarction who underwent coronary revascularization procedures. Serum angiotensin II levels were measured on days 30–40. Patients were divided into groups according to the value of this biomarker. Echocardiography was performed on all patients included in the study on days 30–40 after myocardial infarction; the risk of repeat cardiovascular events was assessed in a 12-month follow-up.

Results. Against the background of routine treatment (including angiotensin-converting enzyme inhibitors) early after infarction, according to the recommendations of the Ministry of Health of the Russian Federation, 10 patients had the elevated angiotensin II level. Significant differences in LV wall thickness and myocardial mass were observed in patients with elevated angiotensin II levels; elevated angiotensin II at 30 to 40 days was not associated with the risk of repeat cardiovascular events in a 12-month follow-up.

Conclusions. Elevated angiotensin II levels are associated with increased left ventricular wall thickness but do not affect the risk of repeat cardiovascular events.

Key words: angiotensin II, myocardial infarction, post-infarction.

REFERENCES

1. Benjamin E.J., Blaha M.J., Chiuve S.E. et al. American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Heart Disease and Stroke Statistics-2017 Update: A Report From the American Heart Association. Circulation, 2017, vol. 135 (10), pp. 146–603.
2. Oparil S., Schmieder R.E. New approaches in the treatment of hypertension. Circ Res., 2015, vol. 116, pp. 1074–1095.
3. Oparil S., Acelajado M.C., Bakris G.L. et al. Hypertension. Nat Rev Dis Primers, 2018, vol. 4, p. 18014.
4. Reinstadler S.J., Stiermaier T., Eitel C., et al. Antecedent hypertension and myocardial injury in patients with reperfused ST-elevation myocardial infarction. Cardiovasc MagnReson., 2016, vol. 18, p. 80.
5. De Luca G., Parodi G., Sciagra R., et al. Impact of hypertension on infarct size in ST elevation myocardial infarction patients undergoing primary angioplasty. J Hypertens, 2013, vol. 31, pp. 2433–2437.
6. Verma K., Pant M., Paliwal S., et al. An Insight on Multicentric Signaling of Angiotensin II in Cardiovascular system: A Recent Update. Front Pharmacol, 2021, vol. 12, p. 734917.
7. Lima R.S., Silva C.D, Lima C.T. et al. Proinflammatory Role of Angiotensin II in the Aorta of Normotensive Mice. Biomed. Res, 2019, vol. 106 (11), pp. 1675–1680.
8. Du Y., Han J., Zhang H., Xu J. et al. Kaempferol Prevents against Ang II-Induced Cardiac Remodeling through Attenuating Ang II-Induced Inflammation and Oxidative Stress. Cardiovas. Pharmacol, 2019, vol. 74 (4), p. 326.
9. Williams B., Mancia G., Spiering W. et al. ESC/ESH Guidelines for the management of arterial hypertension. Eur Heart J, 2018, vol. 39, p. 104.
10. Roostalu U., Thisted L., Skytte J.L. et al. Effect of captopril on post-infarction remodelling visualized by light sheet microscopy and echocardiography. Sci Rep, 2021, vol. 11 (1), p. 5241.
11. Lang R.M., Badano L.P., Mor-Avi V. et al. Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. European Heart Journal: Cardiovascular Imaging, 2015, vol. 16 (3), pp. 233–270.
12. Bhullar S.K., Shah A.K., Dhalla N.S. Mechanisms for the development of heart failure and improvement of cardiac function by angiotensin-converting enzyme inhibitors. Scr. Med., 2022, vol. 53, pp. 51–76.
13. Bhullar S.K., Dhalla N.S. Angiotensin II-Induced Signal Transduction Mechanisms for Cardiac Hypertrophy. Cells, 2022, vol. 11 (21), p. 3336.